# A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors

> **NCT00841191** · PHASE1,PHASE2 · COMPLETED · sponsor: **Centocor, Inc.** · enrollment: 84 (actual)

## Conditions studied

- Ovarian Neoplasms
- Pancreatic Neoplasms
- Colorectal Neoplasms
- Head and Neck Neoplasms
- Lung Neoplasms

## Interventions

- **DRUG:** CNTO 328; Anti-interleukin-6 monoclonal antibody
- **DRUG:** CNTO 328; Anti-interleukin-6 monoclonal antibody
- **DRUG:** CNTO 328; Anti-interleukin-6 monoclonal antibody
- **DRUG:** CNTO 328; Anti-interleukin-6 monoclonal antibody
- **DRUG:** CNTO 328; Anti-interleukin-6 monoclonal antibody
- **DRUG:** CNTO 328; Anti-interleukin-6 monoclonal antibody
- **DRUG:** CNTO 328; Anti-interleukin-6 monoclonal antibody

## Key facts

- **NCT ID:** NCT00841191
- **Lead sponsor:** Centocor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2014-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00841191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00841191, "A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00841191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*